Skip to content
TickerMagic

Sun Pharma Advanced Research Company Limited

SPARCNSEHealthcare
₹192.57
+2.45 (+1.29%) · EOD 2026-11-20

Our verdict

Strong Buy

Financial trend (100/100) does the heavy lifting; momentum (57/100) is the drag.

Buy zoneHealth A
Quality 94Momentum 57Value 92Trend 100The Spark ↓

Our fair value

Undervalued by 100%
₹385.14up 100.00%
Price ₹193Range ₹211 – ₹416

Buy-below (20% margin of safety): ₹308.11

The bottom line

Sun Pharma Advanced Research Company Limited earns a Strong Buy from TickerMagic, with a blended score of 87/100. At ₹192.57 it trades below our blended DCF and relative-multiples fair value of ₹385.14, about 100% upside to that estimate — we read it as undervalued by 100%. On 4.5x trailing earnings it sits cheaper than the Healthcare median of about 37.4x. The price is about 31% below its 52-week high of ₹277.57 and 77% above the low of ₹108.71. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. It clears 10 of 12 investability checks, with durability 94, valuation 83 and momentum 57 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹385.14up 100.00%
Undervalued by 100%
Price ₹192.57Range ₹210.74–₹415.95
Relative multipleslow confidence

With a 20% margin of safety, our buy-below price is ₹308.11. Low-confidence estimate — limited data.

1-year price

EOD · 2026-11-20
1D
up 1.29%
1W
down 9.31%
1M
up 4.05%
3M
down 0.19%
6M
up 7.12%
1Y
—

52-week range

-30.62% from the 52-week high.

Trend check
Above 50-DMA₹193Above 200-DMA₹182

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Strong Buy87
A
Financial health 100/100
Altman Z 5.18 · Safe zone

Piotroski F-score 4/9 — quality of earnings & balance sheet.

Our scores

Durability94
Valuation83
Momentum57

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 10 of 12 checks
Each check screens one fundamentals, valuation or trend signal.
  • Pass: ROE above 15%: 276.9%
  • Pass: Low debt (D/E < 0.5): 0.42x
  • Fail: Positive free cash flow
  • Pass: Revenue growth > 10%: 6717%
  • No data: Earnings growing
  • Pass: Net margin ≥ 10%: 82.7%
  • Pass: Current ratio > 1.5: 2.47
  • Pass: Below our fair value
  • Pass: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Pass: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 5.18
  • Fail: Piotroski ≥ 7: 4/9

Annual financials

Revenue · 2025
₹72 Cr
Net profit
₹-343 Cr
Margin
-477%
2024
2025
Revenue Net profitLatest revenue YoY -5%

Shareholding

  • Promoter75.1%
  • Institutions1.8%
  • Public & other23.1%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹7,017 Cr
P/E ratio
4.5
P/B ratio
5.24
EPS (TTM)
₹47.85
ROE
276.9%
Debt / Equity
0.42x
Profit margin
82.7%
Free cash flow
₹-887 Cr
52-week high
₹277.57
-30.62% from high
52-week low
₹108.71
Dividend yield
—
Beta
0.54
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Strong return on equity (276.9%).
  • Healthy profit margin (82.7%).
  • Financially solid — Altman Z 5.18.

Opportunities

  • Revenue growing (6717% YoY).
  • Trading in our value buy zone versus sector peers.
  • Trades ~100% below our estimated fair value.

About Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research Company Limited is a clinical-stage biopharmaceutical company developing pharmaceutical products focused on oncology and immunology in India and internationally. Its pipeline includes Vodobatinib (SCO-088), a BCR-ABL inhibitor in phase 2 trials for refractory chronic myelogenous leukemia, and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor modulator.

Sun Pharma Advanced Research Company Limited — frequently asked questions

Is Sun Pharma Advanced Research Company Limited a buy, hold or sell?

TickerMagic currently rates Sun Pharma Advanced Research Company Limited (SPARC) a Strong Buy, based on a blended score of 87/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Sun Pharma Advanced Research Company Limited's fair value?

Our blended DCF and relative-valuation model estimates Sun Pharma Advanced Research Company Limited's fair value at about ₹385.14, versus a current price of ₹192.57 — roughly 100% upside. On that basis the stock looks undervalued by 100%.

Is Sun Pharma Advanced Research Company Limited financially healthy?

Sun Pharma Advanced Research Company Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.

How has Sun Pharma Advanced Research Company Limited's share price performed?

Sun Pharma Advanced Research Company Limited is roughly flat over three months, and last traded at ₹192.57. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.